Well. . . we should know by early tomorrow morning.
That $470 million figure is what The Street is expecting. I personally wouldn't be surprised if Kenilworth beats that, breaking $500 million for the quarter -- since it has had a run of good results, from trials. And those should have translated into at least some off-label (or still technically experimental) deployments. We shall see. A bit -- but do go read it all:
. . . .The FDA in October approved Keytruda for the first-line treatment of patients with metastatic NSCLC whose tumors have high expression of PD-L1 with no EGFR or ALK genomic tumor aberrations. . . .
I'll endeavor to live blog anything particularly note-worthy -- but in general I expect an in-line quarter, with some 3 per cent sales headwind, due to currencies. Now you know -- g'night, all.